Amgen Faces Investigation for Data Breach Exposing Sensitive Information

Amgen, a biotech firm based in California, is facing an investigation into a data breach that exposed sensitive information of individuals affiliated with the company. The breach occurred in July 2026 and was discovered when unauthorized activity was identified in Amgen's cloud storage systems hosted by external service providers.

The data breach has been described as 'material' by Amgen, but the exact number of individuals affected remains unknown. As a result, Amgen may have violated state and federal laws by not directly notifying impacted individuals, who may be at risk of identity theft and other serious violations of their privacy.

Schubert Jonckheer & Kolbe LLP is investigating the data breach and has warned that those affected may be entitled to money damages and an injunction requiring changes to Amgen's cybersecurity practices. Individuals who received notification or are affiliated with Amgen can contact the law firm for more information about their legal rights.

Amgen develops and manufactures medicines for serious illnesses, including cancer, cardiovascular disease, inflammation, and rare diseases. The company has not disclosed which data was compromised in the breach, but it may have included proprietary data, patient protected health information, and other sensitive information.